Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26337917 | 0.80 | ALDH1A1 (0.44) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL11977264 | 0.77 | CA1 (0.41) | ALDH1A1P4HTMGRIA1CA1CA2 | |
| SCHEMBL21872080 | 0.76 | P4HTM (0.41) | P4HTMGRIA1CA14 | |
| SCHEMBL28420215 | 0.76 | ALDH1A1 (0.44) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL208469 | 0.76 | GRIA1 (0.37) | P4HTMGRIA1CA2SMN1; SMN2CA14 | |
| SCHEMBL4070679 | 0.76 | NPSR1 (0.48) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL20348772 | 0.75 | ALDH1A1 (0.40) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL23869332 | 0.74 | ALDH1A1 (0.42) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL10254652 | 0.74 | ALDH1A1 (0.47) | ALDH1A1NPSR1CA1CA2CA9 | |
| SCHEMBL24915652 | 0.74 | ALDH1A1 (0.42) | ALDH1A1NPSR1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339929-A1 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2022006340-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021155004-A1 | STRAD-BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | WO | disclosed |
| US-10989846-B2 | Near infrared absorbing composition, near infrared cut filter, method of manufacturing near infrared cut filter, solid image pickup element, camera module, and image display device | FUJIFILM CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| WO-2021050612-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-20180175090-A1 | NEAR INFRARED ABSORBING COMPOSITION, FILM, NEAR INFRARED CUT FILTER, AND SOLID IMAGE PICKUP ELEMENT | FUJIFILM CORPORATION (JP) | 2018-06-21 | — | — | US | disclosed |
| US-20180175090-A1 | NEAR INFRARED ABSORBING COMPOSITION, FILM, NEAR INFRARED CUT FILTER, AND SOLID IMAGE PICKUP ELEMENT | FUJIFILM CORPORATION (JP) | 2018-06-21 | — | — | US | disclosed |
| WO-2018102419-A1 | COMPOUNDS CONTAINING A SULFONIC GROUP AS KAT INHIBITORS | Epizyme, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-7563785-B2 | Quetiapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563785-B2 | Quetiapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090163514-A1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | COUGHLIN DANIEL | 2009-06-25 | — | — | US | disclosed |
| US-7524864-B2 | Methods of treating sleep disorders | HYPNION, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7494998-B2 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7482460-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482460-B2 | Doxepin analogs and methods of use thereof | HYPNION, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | HYPNION, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | GABRB3, GRIN2C, GABRB2 | ALDH1A1 1166/4885NPSR1 86/4885P4HTM 979/4885 |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | GABRA5, GABRE, HCRTR2 | ALDH1A1 1099/4885NPSR1 348/4885P4HTM 611/4885 |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | GABRA5, HCRTR2, HCRTR1 | ALDH1A1 1540/4885NPSR1 205/4885P4HTM 681/4885 |
| US-20230339929-A1 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | SLC10A1, HDGF, NHERF1 | ALDH1A1 430/4885NPSR1 663/4885P4HTM 1446/4885 |
| US-20090163514-A1 | BENZISOXAZOLE PIPERAZINE COMPOUNDS AND METHODS OF USE THEREOF | GABRA5, HCRTR2, HCRTR1 | ALDH1A1 1540/4885NPSR1 205/4885P4HTM 681/4885 |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | ALDH1A1 564/4885NPSR1 278/4885P4HTM 1268/4885 |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | BAX, BCL2, BCL3 | ALDH1A1 4319/4885NPSR1 4769/4885P4HTM 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.